Search Results
Your search for ,twO matches 12124 pages
Showing 11001 - 11050BRAF Inhibition Successful in Relapsed/Refractory BRAF V600E–Mutant Hairy Cell Leukemia
In two phase II studies reported in The New England Journal of Medicine, Tiacci et al found that the BRAF inhibitor vemurafenib (Zelboraf) produced responses in nearly all patients with BRAF V600E–positive hairy cell leukemia who relapsed after treatment with a purine analog or who had...
Synchronous vs Sequential Tumor Resection in Patients With Advanced Colorectal Cancer
About 20% of patients with colorectal cancer have cancers that have metastasized beyond the colon at the time of their diagnosis, with the liver being the most common site for these metastases. The approach to treating primary tumors within the colon and metastatic tumors in the liver continues to...
Internationally Acclaimed Cancer Researcher, Gianni Bonadonna, MD, Dies at 81
Gianni Bonadonna, MD, was considered the “Father of Italian Oncology,” but his scientific contributions to the field and his generous collegial spirit extended far beyond the shores of his native land. Dr. Bonadonna was at the forefront in the battle to convince the surgical...
WCLC: Smoking Cessation Reduces Mortality in Low-Dose Computed Tomography Screening Volunteers
Smoking cessation among patients enrolled in a low-dose computed tomography screening program is associated with a three- to five-time reduction in mortality, according to research (Abstract PLEN04.07) presented at the 16th World Conference on Lung Cancer (WCLC) in Denver, Colorado. The Conference...
FDA Grants Alectinib Priority Review for ALK‑Positive Lung Cancer
Genentech announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) and granted Priority Review for alectinib, an oral investigational anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of people with ALK-positive,...
WCLC: Results From ROMANA Trials of Anamorelin in Advanced NSCLC Patients With Cachexia
Two phase III studies of anamorelin found that the medication effectively combats wasting and increases body weight and lean body mass in certain patients with lung cancer. Results (Abstract ORAL29.01) from the ROMANA 1 and ROMANA 2 phase III trials of anamorelin were presented at the 16th...
FDA Approves Rolapitant for Prevention of Chemotherapy-Induced Nausea and Vomiting
The U.S. Food and Drug Administration (FDA) approved rolapitant (Varubi) to prevent delayed-phase chemotherapy-induced nausea and vomiting. Rolapitant is approved in adults in combination with other antiemetic agents that prevent nausea and vomiting associated with initial and repeat courses of...
Study Finds Modified CAR T Cells Can Selectively Target Solid Tumor Cells While Sparing Healthy Cells
Chimeric antigen receptor (CAR) T cells that are currently being tested to treat B-cell malignancies target a specific protein present on leukemia and lymphoma cells, but these immune cells cannot distinguish the cancer cells from healthy cells. However, the side effects from these CAR T cells...
Activity of Colony-Stimulating Factor-1 Receptor Kinase Inhibitor in Tenosynovial Giant Cell Tumors
In a phase I study reported in The New England Journal of Medicine, Tap et al found that a newly developed inhibitor of colony-stimulating factor-1 receptor (CSF1R) kinase showed activity in tenosynovial giant cell tumors. CSF1 gene expression is elevated in most such tumors. The structure of the...
Preclinical and Clinical Evidence of Lack of Sprouting Angiogenesis in Development of Lymph Node Metastases
In preclinical and clinical studies reported in the Journal of the National Cancer Institute, Jeong et al found a lack of sprouting angiogenesis in the formation of lymph node metastases, suggesting a potential mechanism for resistance to antiangiogenic treatments in adjuvant settings. The study...
Beta-Blockers May Prolong Survival in Women With Ovarian Cancer
In a first-of-its-kind study, researchers demonstrated a benefit in overall survival among patients with epithelial ovarian cancer receiving generic beta-blocker heart medications. Survival was shown to be greatest among those prescribed first-generation nonselective beta-blockers. According to...
Patients With Fewer Than 50 Moles May Be at Risk for More Aggressive Melanoma
People with more than 50 moles have an increased risk of developing melanoma, but those with fewer than 50 moles should still be alert for this disease. In fact, according to new research presented at the American Academy of Dermatology’s 2015 Summer Academy Meeting in New York, those with...
Long-Term Use of Aspirin and Nonsteroidal Anti-inflammatory Drugs May Be Associated With Reduced Colorectal Cancer Risk
A large population-based control study of the use of low-dose aspirin or other nonsteroidal anti-inflammatory drugs and colorectal cancer risk has found that taking 75 mg to 150 mg of aspirin for 5 years or longer was associated with a 27% reduced risk of colorectal cancer. In addition, 5 or more...
FDA Approves Eltrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia
The U.S. Food and Drug Administration approved eltrombopag (Promacta) for the treatment of thrombocytopenia in pediatric patients aged 1 year and older with chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. The approval was...
Rolapitant Reduced Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Cisplatin-Based Chemotherapy
In two phase III trials reported in The Lancet Oncology, Rapoport et al found that the addition of rolapitant to serotonin (5-HT3) receptor antagonist and dexamethasone treatment significantly improved complete response rates in prevention of chemotherapy-induced nausea and vomiting in patients...
Pembrolizumab Cutaneous Adverse Events May Predict Better Response
In a single-center retrospective review reported in JAMA Dermatology, Sanlorenzo et al found that cutaneous adverse events in patients receiving the anti–PD-1 agent pembrolizumab (Keytruda), currently approved for treatment of melanoma, may indicate better treatment response. Study Details...
Adjuvant Taxane-Based Chemotherapy Is Not Associated With Increased Risk of Lymphedema, Study Finds
In women with breast cancer, taxane-based chemotherapy—docetaxel and paclitaxel—did not appear to increase the incidence of lymphedema, according to a study by Swaroop et al in Breast Cancer Research and Treatment. However, the investigators did note that adjuvant chemotherapy with...
Similar Survival With Salvage Surgery After Definitive Chemoradiotherapy vs Neoadjuvant Chemotherapy Followed by Esophagectomy in Esophageal Cancer
In a retrospective European study reported in the Journal of Clinical Oncology, Markar et al found that salvage esophagectomy after definitive chemoradiotherapy was associated with similar survival outcomes vs neoadjuvant chemotherapy followed by planned esophagectomy in treatment of...
Study Finds Music Therapy Lowers Anxiety During Surgical Breast Biopsies
A first-of-its-kind study published by Bradley Palmer et al in the Journal of Clinical Oncology found that music therapy lessened anxiety for women undergoing surgical breast biopsies for cancer diagnosis and treatment. The 2-year study, conducted at University Hospitals (UH) Seidman Cancer Center, ...
FDA Grants Regular Approval to Brentuximab Vedotin as Post-Transplant Consolidation Therapy for High-Risk Classical Hodgkin Lymphoma
The U.S. Food and Drug Administration has approved brentuximab vedotin (Adcetris) as post–autologous hematopoietic stem cell transplantation consolidation treatment for patients with classical Hodgkin lymphoma at high risk of relapse or progression, Seattle Genetics has announced. The...
Study Reveals Effects of Chemoradiation in Brains of Glioblastoma Patients
A study from Massachusetts General Hospital (MGH) Cancer Center researchers—the first to examine the effects of combined radiation and chemotherapy on the healthy brain tissue of glioblastoma patients—revealed not only specific structural changes within patients’ brains, but also...
Preclinical Study Shows MRI and Chemical Contrast Solution Combination Can Detect Breast Cancer Micrometastases
Researchers have shown that magnetic resonance imaging (MRI) can detect the earliest signs of breast cancer recurrence and fast-growing tumors through detecting micrometastases, breakaway tumor cells with the potential to develop into dangerous secondary breast cancer tumors elsewhere in the body....
Malaria-Causing Parasite May Contribute to Development of Burkitt Lymphoma
In an equatorial African region known as the “lymphoma belt,” children are ten times more likely than in other parts of the world to develop Burkitt lymphoma. This area is also plagued by high rates of malaria, and scientists have spent the past 50 years trying to understand how the two ...
Investigational Topical Gel Is Safe and Effective in Patients With Cutaneous T-Cell Lymphoma, Phase I Trial Shows
Results of a phase I trial show that an investigational topical drug, resiquimod gel, causes regression of both treated and untreated tumor lesions and may completely remove cancerous cells from both sites in patients with early-stage cutaneous T-cell lymphoma. Currently, there is no cure for...
Key Genetic Factor in Cell Proliferation in Moles Identified
Scientists have known for years that a mutation in the BRAF gene makes moles start to grow but until now have not understood why they sometimes do not become cancerous. Researchers from the Perelman School of Medicine at the University of Pennsylvania have identified a major genetic factor that...
Addition of Docetaxel to Androgen-Deprivation Therapy Improves Survival in Metastatic Prostate Cancer
In the phase III E3805 trial reported in The New England Journal of Medicine, Sweeney et al found that chemohormonal therapy with docetaxel plus androgen-deprivation therapy produced a significant 13.6-month increase in median overall survival vs androgen-deprivation therapy alone in men with...
Packaging Paclitaxel in Nanoparticles May Increase Drug Efficacy in Preclinical Models
Duke University researchers found that packaging the widely used cancer drug paclitaxel into nanoparticles more than doubled the drug’s effectiveness in destroying tumors in preclinical models. Their findings were published by Bhattacharyya et al in Nature Communications. Paclitaxel has been ...
Study Identifies Genetic Mutations That Predict Response to Chemotherapy in Bladder Cancer
Although cisplatin-based neoadjuvant chemotherapy before cystectomy is the standard of care for muscle-invasive bladder cancer, only between 25% and 50% of patients achieve a pathologic response. A study investigating biomarkers that can predict response to chemotherapy in patients with...
Birinapant in Combination With Carboplatin May Be Effective Against Serous Ovarian Cancer
High-grade serous ovarian cancer often responds well to the chemotherapy drug carboplatin, but it frequently recurs after the first line of treatment. A team of University of California, Los Angeles, researchers has discovered that a subset of tumor cells that don’t produce the protein CA125, ...
Fluorescent Imaging of Lung Lesions During Surgery May Localize Tumors and Improve Precision
More than 80,000 people undergo resection of a pulmonary tumor each year, and currently the only method to determine whether the tumor is malignant is histologic analysis. A new study reported that a targeted molecular contrast agent can be used successfully to render lung adenocarcinomas...
No Difference in Overall Survival With Addition of Quinolone Derivative Vosaroxin to Cytarabine in Relapsed or Refractory AML
In a phase III VALOR trial reported in The Lancet Oncology, Ravandi et al found that the addition of the quinolone derivative vosaroxin to cytarabine did not significantly improve overall survival in patients with relapsed or refractory acute myeloid leukemia (AML). However, differences favoring...
Study Finds Underinvestment in Long-Term Cancer Research
Pharmaceutical firms underinvest in long-term research to develop new cancer-fighting drugs due to the greater time and cost required to conduct such research, according to a newly published study authored by Massachusetts Institute of Technology (MIT) economists. These findings were published by...
Protein Imbalance in Akt Pathway May Trigger Cancer
Cancer can be caused solely by protein imbalance within cells, a study of ovarian cancer has found. Until now, genetic aberrations have been seen as the main cause of almost all cancer. The research, published by Timsah et al in Oncogene, demonstrates that protein imbalance is a powerful prognostic ...
Improved Outcomes With Aromatase Inhibitors vs Tamoxifen in Early Breast Cancer
In a patient-level meta-analysis of randomized trials reported in The Lancet by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), 5 years of aromatase inhibitor treatment significantly reduced the recurrence risk vs 5 years of tamoxifen therapy during the first 4 years and...
Adjuvant Bisphosphonates May Reduce Bone Recurrence and Breast Cancer Mortality in Postmenopausal Women
In a patient-level meta-analysis reported in The Lancet by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), adjuvant bisphosphonate treatment in early breast cancer was associated with a reduced risk of bone recurrence and breast cancer mortality, with the benefit limited to...
NCIC MA.20 Trial: Addition of Regional Nodal Irradiation in Early Breast Cancer Improves Disease-Free but Not Overall Survival
In a phase III trial (National Cancer Institute of Canada [NCIC] Clinical Trials Group MA.20) reported in The New England Journal of Medicine, Whelan et al found that the addition of regional nodal irradiation to whole-breast irradiation did not improve overall survival in women with node-positive...
Leukemia Renewal and Propagation Blocked by Inhibition of Surface Molecule
A new study by researchers at the University of California, San Diego, School of Medicine, reveals a protein’s critical—and previously unknown—role in the development and progression of acute myeloid leukemia (AML). The finding offers a novel target for better treating AML, and...
Omitting Doxorubicin From Postoperative Chemotherapy Has No Significant Survival Effect in Intermediate-Risk Wilms Tumor
In a phase III noninferiority trial (SIOP WT 2001) reported in The Lancet, Pritchard-Jones et al in the SIOP (International Society of Paediatric Oncology) Renal Tumours Study Group found that omission of doxorubicin from postoperative chemotherapy for stage II to III histologic intermediate-risk...
FDA Grants Breakthrough Therapy Designation to Lenvatinib for Metastatic Renal Cell Carcinoma
The U.S. Food and Drug Administration (FDA) granted lenvatinib (Lenvima) Breakthrough Therapy designation for investigational use in patients with advanced or metastatic renal cell carcinoma who were previously treated with a vascular endothelial growth factor (VEGF)-targeted therapy. Lenvatinib...
Researchers Decode Molecular Action of Combination Therapy for Anaplastic Thyroid Cancer
In their bid to find the best combination of therapies to treat anaplastic thyroid cancer, researchers at Mayo Clinic's Florida campus demonstrated that all histone deacetylase (HDAC) inhibitors are not created equal. In testing multiple HDAC inhibitors in combination with the chemotherapy drug...
FDA Approves Carfilzomib Combination for Patients With Relapsed Multiple Myeloma
The U.S. Food and Drug Administration (FDA) approved carfilzomib (Kyprolis) in combination with lenalidomide (Revlimid) and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. The approval was based on a demonstration of ...
FDA Approves Sonidegib for Locally Advanced Basal Cell Carcinoma
The U.S. Food and Drug Administration (FDA) approved sonidegib (Odomzo) for the treatment of patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy or those who are not candidates for surgery or radiation therapy. The approval was based on...
No Survival Benefit of Adding MET Inhibitor Tivantinib to Erlotinib in Previously Treated Advanced Nonsquamous NSCLC
In a phase III trial reported in the Journal of Clinical Oncology, Scagliotti et al found that the addition of the MET receptor tyrosine kinase inhibitor tivantinib to erlotinib (Tarceva) did not improve overall survival in previously treated patients with locally advanced or metastatic nonsquamous ...
Early Lapatinib and Trastuzumab Active in HER2-Positive Metastatic Breast Cancer
Lapatinib plus trastuzumab improves outcomes vs lapatinib in heavily pretreated HER2-positive metastatic breast cancer. In the phase II TBCRC 003 study reported in the Journal of Clinical Oncology, Lin et al found that earlier use of lapatinib plus trastuzumab was active in HER2-positive metastatic ...
New Analysis Points the Way to Earlier Diagnosis of Pediatric Chest Tumors
Researchers led by St. Jude Children’s Research Hospital scientists have developed new diagnostic criteria to enable clinicians to distinguish malignant cancerous chest cavity masses from those caused by fungal histoplasmosis infection. Their findings were published by Naeem et al in the...
T-cell Receptor Therapy Achieves Encouraging Clinical Responses in Multiple Myeloma
Results from a clinical trial investigating a new T-cell receptor therapy demonstrated a clinical response in 80% of patients with multiple myeloma who had advanced disease after undergoing autologous stem cell transplants. Researchers at Penn’s Abramson Cancer Center modified T cells to ...
Low Incidence of Infusion-Related Reactions Reported With 30-Minute Ipilimumab Infusion
In a single-institution study reported in the Journal of Clinical Oncology, Momtaz et al found that the rate of infusion-related reactions remained acceptably low when ipilimumab (Yervoy) 3 mg/kg was infused over 30 minutes in patients with advanced melanoma. The currently approved dose of...
Study Finds One-Third of Colorectal Cancers Diagnosed Before Age 35 Are Hereditary
Although the prevalence of genetic risk factors, such as Lynch syndrome and familial adenomatous polyposis, has been studied in the general population of individuals with colorectal cancer, patients diagnosed as adolescents and young adults are not well represented in colorectal cancer studies. A...
Adding Neoadjuvant mFOLFOX6 After Chemoradiation May Improve Pathologic Complete Response Rate in Locally Advanced Rectal Cancer
In a phase II trial reported in The Lancet Oncology, Garcia-Aguilar et al found that adding neoadjuvant mFOLFOX6 (modified fluorouracil [5-FU], leucovorin, oxaliplatin) after chemoradiation improved the pathologic complete response rate in patients with locally advanced rectal cancer undergoing...
Trial Shows Molecular Subtypes of Diffuse Large B-Cell Lymphoma React Differently to Ibrutinib
A clinical trial has shown that patients with a specific molecular subtype of diffuse large B-cell lymphoma are more likely to respond to ibrutinib (Imbruvica) than patients with another molecular subtype of the disease. The study was published by Wilson et al in Nature Medicine. In this phase II...
